-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on AbbVie, Raises Price Target to $227

Benzinga·08/01/2025 14:22:01
Listen to the news
Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $216 to $227.